文献速递眼底病与葡萄膜炎

韩国患者玻璃体腔注射地塞米松植入剂后眼压变化

Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients.
PubMed 文献 · Br J Ophthalmol · 2018-12-06

该回顾性观察研究纳入503例(540眼)因多种视网膜疾病导致黄斑水肿并接受玻璃体腔地塞米松(DEX,Ozurdex)植入剂注射的韩国患者,分析注射后1年内眼压变化。结果显示平均眼压至注射后2个月逐渐升高,之后逐渐下降;眼压升高发生率为12.6%,需治疗者11.1%,仅0.2%最终需手术干预,低于既往西方人群研究报道。

要点

  • DEX植入后平均眼压2个月达峰值16.85±5.96 mmHg,12个月回落至13.80±4.04 mmHg。
  • 眼压>25 mmHg者10.6%、>30 mmHg者5.4%、>35 mmHg者1.7%,较基线升高>10 mmHg者11.3%。
  • 总体眼压升高发生率12.6%,需降眼压药物者10.9%,需手术者0.2%。

核心结论

  • 韩国患者玻璃体腔DEX植入后需长期降眼压药物及手术干预的眼压升高发生率显著低于既往西方人群研究报道。
  • 玻璃体腔DEX注射可能是亚洲黄斑水肿患者有效且相对安全的治疗方式。

研究设计与样本

  • 回顾性观察研究,纳入503例患者共540眼,均因多种视网膜疾病导致黄斑水肿接受DEX植入剂注射。
  • 在注射前及注射后1周、1个月、2个月、3个月、6个月、12个月测量眼压。
  • 眼压升高分为四类:注射后眼压>35 mmHg、>30 mmHg、>25 mmHg,以及相对基线升高>10 mmHg。

主要发现

  • 平均基线眼压为13.45±2.95 mmHg。
  • 平均眼压逐渐升高至注射后2个月(16.85±5.96 mmHg,p<0.001),之后逐渐下降至注射后12个月(13.80±4.04 mmHg,p=0.16)。
  • 眼压>25 mmHg者57眼(10.6%),>30 mmHg者29眼(5.4%),>35 mmHg者9眼(1.7%)。
  • 眼压较基线升高>10 mmHg者61眼(11.3%)。
  • 总体眼压升高发生率为12.6%(68眼)。

关键数值与推荐

  • 68眼(12.6%)眼压升高者中,60眼(11.1%)需要治疗。
  • 59眼(10.9%)需要降眼压药物治疗,1眼(0.2%)最终需要手术干预。

临床怎么用

  • 对亚洲黄斑水肿患者行玻璃体腔DEX植入后应规律监测眼压,尤其注射后2个月内。
  • 多数眼压升高可通过降眼压药物控制,需手术干预者比例很低。

局限性

  • 本研究为回顾性观察研究。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To analyse intraocular pressure (IOP) changes over a period of 1 year after intravitreal dexamethasone (DEX, Ozurdex) implant injection and to compare the results with those of previously published studies that involved non-Asian populations. METHODS: A retrospective observational study was conducted. A total of 540 eyes of 503 patients who received DEX implant injection and were diagnosed with macular oedema (ME) due to various retinal diseases were examined. IOP was measured prior to injection and at 1 week, 1 month, 2 months, 3 months, 6 months and 12 months after DEX implant injection. IOP elevation was divided into four categories: postinjection IOP of >35 mm Hg, >30 mm Hg and >25 mm Hg, and an IOP elevation of >10 mm Hg, relative to the baseline measurement. RESULTS: The mean baseline IOP was 13.45±2.95. The mean IOP gradually increased until 2 months postinjection (IOP=16.85±5.96 mm Hg, p<0.001) and then gradually decreased until 12 months postinjection (IOP=13.80±4.04mm Hg, p=0.16). IOP was >25 mm Hg in 57 eyes (10.6%), >30mm Hg in 29 eyes (5.4%) and >35mm Hg in 9 eyes (1.7%); IOP exhibited >10 mm Hg elevation from the baseline IOP in 61 eyes (11.3%). Overall, the incidence rate of IOP elevation after DEX treatment was 12.6% (68 eyes). Among the 68 eyes (12.6%) with elevated IOP, 60 (11.1%) required treatment: 59 (10.9%) required IOP-lowering medication and 1 (0.2%) ultimately required surgical interventions. CONCLUSIONS: The incidence of adverse IOP elevation requiring the prolonged use of IOP-lowering medication and surgical intervention after DEX implantation was significantly lower than the incidence reported in previous Western population-based studies. Intravitreal DEX injection may therefore be an effective and relatively safe treatment modality for ME in Asian patients.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Choi W, Park SE, Kang HG, et al. Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients. Br J Ophthalmol. 2018. PMID: 30523044. doi:10.1136/bjophthalmol-2018-312958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。